Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7955)	5/18/2000 5:02:00 PM
From: nigel bates	Read Replies (1) \| Respond to of 9719

And... May 18 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news) announced today that American Home Products Corporation (AHP) (NYSE: AHP - news) has exercised its option to obtain a non-exclusive license under PDL's antibody humanization patents to market Mylotarg(TM) (gemtuzumab ozogamicin for injection) in Japan and other Asian countries. AHP had obtained a non-exclusive license in 1999 under PDL's antibody humanization patents to market Mylotarg in other territories including the U.S. and Europe; AHP and Mylotarg were not identified at that time. PDL will receive an additional non-refundable, non-creditable signing and licensing from AHP and will be entitled to annual maintenance fees and royalties on any Mylotarg sales.